Skip to main content
logo
Lyra Therapeutics, Inc. (LYRA)
OTCMKTS · Delayed Price · Currency is USD
0.2800
-0.0600 (-17.65%)
At close: Aug 10, 2026

Lyra Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingSep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Revenue
0.61.531.561.360.29-
Revenue Growth
-59.21%-1.54%14.31%378.25%--
Gross Profit
0.61.531.561.360.29-
Operating Income
-35.31-96.35-67.12-56.31-43.62-22.21
Net Income
-32.95-93.44-62.68-55.28-43.51-22.13
Earnings Per Share
-23.44-71.50-63.00-91.50-167.50-129.50
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingSep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Cash & Investments
22.0640.58102.7597.8945.7574.59
Total Debt
31.3834.3826.882.221.452.44
Net Cash (Debt)
-9.326.275.8795.6844.2972.15
Net Cash Growth
--91.83%-20.70%116.01%-38.61%1013.14%
Net Cash Per Share
-6.504.7676.17158.22170.54419.98

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingSep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Operating Cash Flow
-34.15-70.01-63.3-43.39-25.82-21.14
Capital Expenditures
0.04-2.34-1.05-0.16-3.39-1.78
Free Cash Flow
-34.11-72.35-64.35-43.55-29.21-22.92
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingSep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Gross Margin
100.00%100.00%100.00%100.00%100.00%-
Operating Margin
-5885.33%-6280.83%-4308.09%-4131.03%-15303.51%-
Pretax Margin
-5488.67%-6088.40%-4019.32%-4054.66%-15267.72%-
Profit Margin
-5491.17%-6090.94%-4023.11%-4055.61%-15267.72%-
FCF Margin
-5684.50%-4716.36%-4130.36%-3195.08%-10247.37%-

Valuation
Chart
Fiscal YearCurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingAug '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
PS Ratio
1.258.82192.4373.32198.99-